• Home >>
  • Pharmaceuticals and Healthcare >>
  • Insulin Market: Global Market Synopsis, Growth Factors, Industry Segmentation, Regional Analysis And Competitive Analysis 2017 - 2025

Insulin Market: Global Market Synopsis, Growth Factors, Industry Segmentation, Regional Analysis And Competitive Analysis 2017 - 2025

ID: 129255 March, 2018 Region : Global Pages
Covid-19

COVID-19

Understand the influence of COVID-19 on the Insulin Market with our analysts monitoring the situation across the globe.

Global insulin market, by product (short-acting insulin, intermediate-acting insulin, long-acting insulin, premixed insulin), drug (generic drugs, branded drugs) and disease (type 1 diabetes, type 2 diabetes).
Market Scenario:

Insulin regulates carbohydrates, fats and proteins metabolism in the body. The human insulin protein is composed of 51 amino acids. Insulin is a peptide hormone produced by beta cells of the pancreatic islets, and it is considered to be the main anabolic hormone of the body. It absorbs glucose from the blood and flow to liver, fat and skeletal muscle cells. The use of insulin is increasing due to predominance of diabetes and obesity. 


The major driver for insulin market is growing obesity and diabetes prevalence all over the world. Also extensive & well-established distribution network of insulin drugs in developed as well as fast developing countries boost the insulin market growth. Heavy investments in research and development of insulin products drive this market. However, stringent regulatory requirements for product approval are restraining the growth of this market. The major challenges for insulin market will be, continuously growing competition among the manufacturers and suppliers, regulatory pressure, insurance coverage issues and high insulin cost. 


Segmentation:

The global insulin market is segmented on the basis of product, drug and disease.
On the basis of product, the market is segmented into short-acting insulin, intermediate-acting insulin, long-acting insulin, premixed insulin.
On the basis of drug, the market is segmented into generic drugs, branded drugs.

On the basis of disease, the market is segmented into type 1 diabetes, type 2 diabetes.


Regional Analysis:

Geographically, the insulin market is segregated in North America, Europe, Asia Pacific, Middle East & Africa and LAMEA. North American region is the global leader in insulin market in terms of values and extent due to high prevalence of diabetes and technological advances in effective insulin delivery.  However, Asia-Pacific and LAMEA are the fastest growing geographic segments due to high diabetes incidences, government support and improving healthcare conditions. 


Key Players:
The major key players in insulin market such as, Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Biocon, Tonghua Dongbao Pharmaceutical Co., Ltd., Adocia, Merck & Co., Inc., Pfizer, Inc., Wockhardt, Julphar, Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Oramed Pharmaceuticals, Inc. and Other. These players are trying to recognise the needs of market in developing countries and expanding their strategies to improve business needs.


Segmentation:
By Product
• Short-Acting Insulin
• Intermediate-Acting Insulin
• Long-Acting Insulin
• Premixed Insulin
By Drug
• Generic Drugs
• Branded Drugs
By Disease
• Type 1 Diabetes
• Type 2 Diabetes

Research Scope
The study for Global Insulin Market Survey and Trend Research 2018 will provide market size, estimates and forecast based on the following years: 
 
Historic data: 2015  Base Year Estimate: 2016  Forecast: 2017 to 2025


The report has been categorized in two distinctive sections, where the first category titled as Market Overview provides a holistic view of the market, key trends, drivers, challenges/restraints or opportunities with their current and expected impact on the overall industry sales. 
Our analyst implement, several qualitative tools such as Ansoff’s Matrix, PESTEL analysis, Porter’s five force analysis among other to interpret and represent key industry findings. 
The second section of the study provides market size, estimates and forecast for key market segments and regional market. The final part of the report highlights key manufacturers/vendors operating in the associated market. 

1. Introduction

1.1. Market Definition
1.2. Market Scope


2. Research Methodology
2.1. Primary Research
2.2. Secondary Sources
2.3. Assumptions & Exclusions


3. Market Overview
3.1. Research Report Segmentation & Scope
3.2. Key Market Trend Analysis
3.2.1. Market Drivers
3.2.2. Market Restraint/Challenges
3.2.3. Market Opportunities
3.3. Porter’s Five Forces Analysis
3.4. Potential Venture Avenues
3.5. Market Share Analysis, 2016 


4. Product Type Overview
4.1. Introduction 
4.2. Market Size & Forecast, 2015 to 2025
4.2.1. Short-Acting Insulin
4.2.2. Intermediate-Acting Insulin
4.2.3. Long-Acting Insulin
4.2.4. Premixed Insulin
 (Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)


5. Drug Type Overview
5.1. Introduction 
5.2. Market Size & Forecast, 2015 to 2025
5.2.1. Generic Drugs
5.2.2. Branded Drugs
 (Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)

6. Disease Overview

6.1. Introduction 
6.2. Market Size & Forecast, 2015 to 2025
6.2.1. Type 1 Diabetes
6.2.2. Type 2 Diabetes
(Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)


7. Regional Overview
7.1. Introduction
7.2. Market Size & Forecast, 2015 to 2025
7.2.1. North America
7.2.1.1. U.S.
7.2.1.2. Canada
7.2.1.3. Mexico 
7.2.2. Europe
7.2.2.1. UK
7.2.2.2. Germany
7.2.2.3. France
7.2.2.4. Italy 
7.2.2.5. Russia
7.2.2.6. Poland
7.2.2.7. Rest of Europe
7.2.3. Asia-Pacific
7.2.3.1. China
7.2.3.2. India
7.2.3.3. Japan
7.2.3.4. Australia
7.2.3.5. South Korea
7.2.3.6. Rest of Asia-Pacific
7.2.4. LAMEA
7.2.4.1. Saudi Arabia
7.2.4.2. UAE
7.2.4.3. South Africa
7.2.4.4. Rest of LAMEA
(Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)


8. Manufacturer/ Vendor Profile
8.1. The following attributes will be considered while profiling key manufacturers in this industry: 
8.1.1. Company Overview
8.1.2. Financial Synopsis
8.1.3. Recent Developments
8.1.4. R&D Investments (if any)
8.1.5. Strategy Overview (Analyst Perspective)
8.1.6. Product Portfolio
8.2. Companies Profiled
8.2.1. Novo Nordisk A/S, Eli Lilly and Company
8.2.2. Sanofi
8.2.3. Biocon
8.2.4. Tonghua Dongbao Pharmaceutical Co., Ltd.
8.2.5. Adocia
8.2.6. Merck & Co. Inc.
8.2.7. Pfizer Inc.
8.2.8. Wockhardt
8.2.9. Julphar
8.2.10. Bristol-Myers Squibb Company
8.2.11. GlaxoSmithKline Plc
8.2.12. Oramed Pharmaceuticals Inc.
8.2.13. Other
 (Note: The companies mentioned above are tentative in nature, and profiles of other market players not listed here can be included on request.) 

Request COVID-19 Impact Analysis

We understand the economic repercussions of the pandemic and are dedicated towards helping our clients strategize with rapidly changing market scenario,
• Impact of COVID on supply/demand scenario, trade landscape & supply chain
• How market participants are preparing/strategizing to combat the impact
• How does the short-term & long-term scenario for Insulin Market looks like

Name*

Email*

Phone*

Name of the Company*

Title/ Designation*

Select Country*

How can we help you?

Request Sample

Name*

Email*

Phone*

Name of the Company*

Title/ Designation*

Select Country*

How can we help you?

Request Discount

Name*

Email*

Phone*

Name of the Company*

Title/ Designation*

Select Country*

How can we help you?

Related Reports




Get 15 minutes of free Consultation When you request a Sample Report!

24/7 Research Report

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone:

+1 513 549 5911 (US)

+44 203 318 2846 (UK)

Email: [email protected]